We reserve the right to block IP addresses that submit excessive requests. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. More Information Internet Security Policyīy using this site, you are agreeing to security monitoring and auditing. For more information, contact more information, please see the SEC’s Web Site Privacy and Security Policy. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. Please declare your traffic by updating your user agent to include company specific information.įor best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. Your request has been identified as part of a network of automated tools outside of the acceptable policy and will be managed until action is taken to declare your traffic. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Philadelphia, PA: Chemical Heritage Foundation.Your Request Originates from an Undeclared Automated Tool Schoemaker (1950–2006) An Oral History (PDF). Marks, Lara Everson, Ted Dionisio, Jen, eds.^ 'Venture-Backed Garnet BioTherapeutics, Inc.^ 'Company Overview of Garnet Biotherapeutics, Inc'.'Reducing tissue damage after a heart attack'. (2012) 'The birth pangs of monoclonal antibody therapeutics', mAbs, 4 (3), 1-10. (2009) 'Collaboration - a competitor's tool: The story of Centocor, an entrepreneurial biotechnology company', Business History, 51(4): 529-46. Philadelphia, PA: Chemical Heritage Foundation. ^ a b Marks, Lara Everson, Ted Dionisio, Jen, eds.'Hubert Schoemaker, a Biotech Pioneer, Dies at 55'. ^ a b Pollack, Andrew (January 13, 2006).Schoemaker was diagnosed in 1994 with a form of brain cancer, medulloblastoma. ReoPro was to be followed in August 1998 by the approval of Centocor's Remicade, a drug to treat auto-immune disorders like Crohn's disease and rheumatoid arthritis. The first therapeutic to ever receive simultaneous US and European approvals, and the second monoclonal antibody to ever win approval as a drug, ReoPro marked a milestone for both Centocor and for monoclonal antibodies therapeutics. Learning from its mistakes with Centoxin, in December 1994 Centocor gained marketing approval for ReoPro, a monoclonal antibody drug for cardiovascular disease. What saved the company was a return to the policy of collaboration. In part the crisis had come about as a result of the company's executives trying to go it alone in developing the drug. Despite the company's success on the diagnostic front, Schoemaker was plunged in 1992 into efforts to save the company from bankruptcy when its first therapeutic, Centoxin, a drug designed to treat septic shock, failed to win FDA approval.
0 Comments
Leave a Reply. |